blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2563390

EP2563390 - METHODS AND ARTICLES FOR PREVENTING OR REDUCING RISK OF DEVELOPING A HYPERALLERGENIC IMMUNE SYSTEM [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  24.11.2017
Database last updated on 14.09.2024
Most recent event   Tooltip24.11.2017Refusal of applicationpublished on 27.12.2017  [2017/52]
Applicant(s)For all designated states
Allovate, LLC
100 West 93rd Street, Unit 15F
New York NY 10025 / US
[2013/10]
Inventor(s)01 / FRANCOIS, Cedric
1434 Goddard Avenue
Louisville, KY 40204 / US
 [2013/10]
Representative(s)Moore, Michael Richard, et al
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
[N/P]
Former [2013/10]Moore, Michael Richard, et al
Keltie LLP
Fleet Place House
2 Fleet Place
London EC4M 7ET / GB
Application number, filing date11775689.002.05.2011
WO2011US34741
Priority number, dateUS20100329726P30.04.2010         Original published format: US 329726 P
[2013/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011137422
Date:03.11.2011
Language:EN
[2011/44]
Type: A2 Application without search report 
No.:EP2563390
Date:06.03.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2011 takes the place of the publication of the European patent application.
[2013/10]
Search report(s)International search report - published on:US22.12.2011
(Supplementary) European search report - dispatched on:EP16.04.2014
ClassificationIPC:A61K39/36
[2013/10]
CPC:
A61K39/36 (EP,US); A61J7/0053 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/10]
TitleGerman:VERFAHREN UND ARTIKEL ZUR VERHINDERUNG ODER REDUZIERUNG DES RISIKOS DER ENTWICKLUNG EINES HYPERALLEGENEN IMMUNSYSTEMS[2013/10]
English:METHODS AND ARTICLES FOR PREVENTING OR REDUCING RISK OF DEVELOPING A HYPERALLERGENIC IMMUNE SYSTEM[2013/10]
French:PROCÉDES ET ARTICLES DE PRÉVENTION OU DE RÉDUCTION DU RISQUE DE DÉVELOPPEMENT D'UN SYSTÈME IMMUNITAIRE HYPERALLERGÉNIQUE[2013/10]
Entry into regional phase30.11.2012National basic fee paid 
30.11.2012Search fee paid 
30.11.2012Designation fee(s) paid 
30.11.2012Examination fee paid 
Examination procedure30.11.2012Examination requested  [2013/10]
14.11.2014Amendment by applicant (claims and/or description)
04.01.2016Despatch of a communication from the examining division (Time limit: M06)
14.07.2016Reply to a communication from the examining division
10.07.2017Application refused, date of legal effect [2017/52]
10.07.2017Date of oral proceedings
04.08.2017Despatch of communication that the application is refused, reason: substantive examination [2017/52]
04.08.2017Minutes of oral proceedings despatched
Divisional application(s)EP17179648.5
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.01.2016
Fees paidRenewal fee
28.05.2013Renewal fee patent year 03
27.05.2014Renewal fee patent year 04
27.05.2015Renewal fee patent year 05
27.05.2016Renewal fee patent year 06
30.05.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]EP0681824  (WIMA KUNSTSTOFF PRODUKTE GMBH [DE]) [X] 1 * the whole document * [Y] 2,3,12-15;
 [XY]WO9825572  (CROWE D E [US], et al) [X] 1 * the whole document * [Y] 2,3,12-15;
 [XY]DE29912596U  (CHEN CHEAN SHUI [TW]) [X] 1 * the whole document * [Y] 2,3,12-15;
 [A]DE10137232  (FOSS PIERRE [DE]) [A] 1-3,12-15 * the whole document *;
 [Y]  - ESCH R E ET AL, "Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, ARLINGTON HEIGHTS, IL, US, vol. 100, no. 5, ISSN 1081-1206, (20080501), pages 475 - 481, (20080501), XP026960057 [Y] 1-15 * the whole document *
 [Y]  - MARCUCCI F ET AL, "Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites.", ALLERGY JUL 2003, (200307), vol. 58, no. 7, ISSN 0105-4538, pages 657 - 662, XP002722732 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1034/j.1398-9995.2003.00193.x
 [Y]  - T HIRSCH ET AL, "Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children.", PEDIATRIC ALLERGY AND IMMUNOLOGY, DK, (19970201), vol. 8, no. 1, doi:10.1111/j.1399-3038.1997.tb00138.x, ISSN 0905-6157, pages 21 - 27, XP055111776 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1399-3038.1997.tb00138.x
 [Y]  - SKONER D ET AL, "Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 125, no. 3, doi:10.1016/J.JACI.2009.12.931, ISSN 0091-6749, (20100301), pages 660 - 666.e4, (20100211), XP026942662 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jaci.2009.12.931
 [Y]  - TAHAMILER RAUF ET AL, "Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.", THE LARYNGOSCOPE JUN 2007, (200706), vol. 117, no. 6, ISSN 0023-852X, pages 965 - 969, XP002722733 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1097/MLG.0b013e31804f8141
 [Y]  - MARCUCCI F ET AL, "Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.", ALLERGY NOV 2001, (200111), vol. 56, no. 11, ISSN 0105-4538, pages 1091 - 1095, XP002722786 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1034/j.1398-9995.2001.00226.x
 [Y]  - "[The Nutrition Committee of the Austrian Society of Pediatrics. Antigen-reduced infant nutrition].", PÄDIATRIE UND PÄDOLOGIE 1993, (1993), vol. 28, no. 4, ISSN 0030-9338, pages 93 - 95, XP008168669 [Y] 1-15 * the whole document *
 [A]  - MASCARELL LAURENT ET AL, "Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines.", IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA MAY 2006, (200605), vol. 26, no. 2, ISSN 0889-8561, page 283, XP008168661 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.iac.2006.02.009
International search[Y]WO9517208  (INST CHILD HEALTH RESEARCH OF [AU], et al);
 [Y]US5762943  (DOLOVICH JERRY [CA], et al);
 [Y]WO2008153761  (MASTCELL PHARMACEUTICALS INC [US], et al);
 [Y]US2009182308  (HAGBI IDAN [IL])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.